Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03794349
Title Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Children's Oncology Group
Indications

ganglioneuroblastoma

neuroblastoma

Therapies

Dinutuximab + Irinotecan + Sargramostim + Temozolomide

Dinutuximab + Eflornithine + Irinotecan + Sargramostim + Temozolomide

Age Groups: adult | child | senior
Covered Countries USA | CAN


No variant requirements are available.